

# Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance

ST. PAUL, Minn., March 12, 2025 /PRNewswire/ -- [Solventum](#) (NYSE: SOLV), formerly 3M Health Care, today announced the launch of the Attest™ eBowie-Dick Test System (eBowie-Dick System), an electronic test card and auto-reader for sterilization testing that eliminates the need for visual interpretation of results and manual documentation.

In less than five seconds, the eBowie-Dick System's simple "pass" or "fail" digital display provides definitive test results and creates an automated record that can be integrated into a hospital's instrument tracking system, eliminating the need to scan analog test results.

Traditional tests for steam dynamic-air removal sterilizers use a color-changing ink indicator to evaluate the efficacy of air removal and detect leaks in the sterilizer. The ink indicator is tucked between layers of a paper packet. The paper is discarded when the ink indicator is removed from the packet to assess the test results.

The eBowie-Dick Test System can reduce the paper waste from Bowie-Dick tests entering a hospital's waste stream by 94% compared to paper waste generated by traditional Bowie-Dick Test Packs.

"Our new eBowie-Dick System revolutionizes sterilization testing by reducing processing times, eliminating the variability inherent to traditional methods, and the device's software capabilities provide advanced analytics not possible with today's tests," said Chris Barry, executive vice president, group president, Medical Surgical, Solventum. "Through digitization, Solventum is saving sterilization assurance professionals time and reducing waste to help create a more sustainable future."

The eBowie-Dick System is now available in the United States from authorized distribution partners and will roll out globally throughout 2025\*\*.

## **About Solventum**

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at [Solventum.com](#).

## **Forward-Looking Statements**

This news release contains forward-looking information about Solventum's financial results, estimates, and business prospects that involve substantial risks and uncertainties. In particular, statements regarding the future performance of Solventum, including guidance for 2024, are forward-looking statements. You can identify these statements by the use of words such as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to our reputation or our brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events; (5) Solventum's business dealings involving third-party partners in various markets; (6) Solventum's ability to access the capital and credit markets and changes in Solventum's credit ratings; (7) exposure to interest rate and currency risks; (8) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (9) reduction in customers' research budgets or government funding; (10) the timing and market acceptance of Solventum's new product and service offerings; (11) ongoing working relationships with certain key healthcare professionals; (12) changes in reimbursement practices of governments or private payers or other cost containment measures; (13) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (14) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, Foreign Corrupt Practices Act (FCPA) and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (15) potential liabilities related to a broad group of perfluoroalkyl and polyfluoroalkyl substances, collectively known as "PFAS"; (16) risks related to the highly regulated environment in which Solventum operates; (17) risks associated with product liability claims; (18) climate change and measures to address climate change; (19) security breaches and other disruptions to information technology infrastructure; (20) Solventum's failure to obtain,

maintain, protect, or effectively enforce its intellectual property ("IP") rights; (21) pension and postretirement obligation liabilities; (22) any failure by the 3M Company ("3M") to perform any of its obligations under the various separation agreements in connection with the separation from 3M (the "Spin-Off"); (23) any failure to realize the expected benefits of the Spin-Off, and/or that the Spin-Off will not be completed within the expected time frame, on the expected terms or at all; (24) a determination by the IRS or other tax authorities that the distribution or certain related transactions should be treated as taxable transactions; (25) expected financing transactions undertaken in connection with the separation and risks associated with additional indebtedness; (26) the risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the separation will exceed Solventum's estimates; and (27) the impact of the Spin-Off on its businesses and the risk that the Spin-Off may be more difficult, time-consuming or costly than expected, including the impact on its resources, systems, procedures and controls, diversion of management's attention and the impact on relationships with customers, suppliers, employees and other business counterparties.

Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

\*Compared to waste generated by 3M Bowie-Dick paper test packs. Waste mass based on eBowie-Dick10135B product and packaging case weight, with percent calculated on per test basis.

\*\*Some countries may be delayed due to additional local regulatory requirements

SOURCE Solventum

For further information: For further information: Investor Contact: [investors@solventum.com](mailto:investors@solventum.com); or Media Contact: [news@solventum.com](mailto:news@solventum.com)

---

Additional assets available online:  [Photos \(1\)](#)

<https://investors.solventum.com/2025-03-12-Solventum-Launches-Attest-TM-eBowie-Dick-Test-System-Revolutionizing-Sterilization-Assurance>